Skip to main content
. 2015 May 28;10(5):e0127628. doi: 10.1371/journal.pone.0127628

Fig 7. PAR4-induced mechanical hypersensitivity is partially reduced by CXCR4 antagonist, AMD3100.

Fig 7

Intravesical PAR4-AP treatment resulted in a significant increase in % positive responses with every filament strength tested (see Fig 4E). Pre-treatment with a CXCR4 antagonist, AMD3100 (10 mg/kg; i.p.), 15 minutes before AP, reduced the PAR4-AP-induced % response increase from respective baseline (* p ≤ 0.05).